Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1995-05-30
2003-01-28
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S139100, C424S141100, C424S142100, C424S143100, C424S144100, C424S152100, C424S153100, C424S173100, C530S387100, C530S387300, C530S387900, C530S388100, C530S388150, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750, C435S331000, C435S334000, C435S343200, C435S346000
Reexamination Certificate
active
06511665
ABSTRACT:
TECHNICAL FIELD
The present invention relates generally to antibodies and, more specifically, to antibodies against interleukin-1 receptors.
BACKGROUND OF THE INVENTION
Interleukin-1&agr; and Interleukin-1&bgr; (IL-1&agr; and IL-1&bgr;) are distantly related polypeptide hormones which play a central role in the regulation of immune and inflammatory responses. These two proteins were originally both classified as IL-1, based on a shared lymphocyte activation factor (LAF) activity, and a common major cellular source, activated macrophages. As information has accumulated from studies using purified natural and recombinant IL-1 molecules, it has become clear that IL-1&agr; and IL-1&bgr; each mediate most, if not all, of the wide range of activities previously ascribed to IL-1. The basis for this nearly identical spectrum of biological activities is thought to be a single class of plasma membrane IL-1 receptors which bind both IL-1&agr; and IL-1&bgr;. The binding of IL-1 to these receptors is specific, and occurs with a high affinity (1×10
−10
M).
Polyclonal antibodies have long been utilized for various aspects of research and development, but in 1975 Köhler and Milstein discovered a new technique which revolutionized the production and use of antibodies (see Köhler and Milstein,
Nature
256:495 1975). This technique utilized somatic cell hybridization to generate a continuous “hybridoma” cell line which produced large quantities of a single specific antibody, also referred to as a monoclonal antibody.
It would be beneficial if such antibodies against the IL-1 receptor were available, as they may be useful for diagnosis and therapy, as well as for various research applications. For example, antibodies may be utilized in clinical applications to diagnose the presence of IL-1 receptor in a patient's serum, or may be administered therapeutically to bind to and target IL-1 receptor bearing cells for elimination or neutralization. Additionally, antibodies may be utilized in various research applications such as the purification of recombinantly produced IL-1 receptor, or in assays which detect the presence of the IL-1 receptor.
The present invention provides such antibodies and, furthermore, provides other related advantages.
SUMMARY OF THE INVENTION
The present invention provides monoclonal antibodies which specifically bind to mammalian IL-1 receptors. Within one embodiment of the invention, the monoclonal antibody is selected from the group consisting of human and mouse monoclonal antibodies. Within selected embodiments, the monoclonal antibody blocks the binding of IL-1 to the IL-1 receptor. Within another embodiment the mammalian IL-1 receptor is selected from the group consisting of murine and human IL-1 receptor. Within a related aspect, a therapeutic composition is provided comprising a monoclonal antibody to the IL-1 receptor as described above and a physiologically acceptable carrier or diluent.
Within another aspect of the present invention, a binding protein is provided which specifically binds to a mammalian IL-1 receptor, which may be, for example, a fragment of an antibody or a fusion protein comprising at least one domain derived from an antibody. Within a related aspect, a therapeutic composition is provided comprising a binding protein which specifically binds to mammalian IL-1 receptor, and a physiologically acceptable carrier or diluent.
Within yet another aspect of the present invention, a method for detecting IL-1 receptors on cells is provided comprising the steps of (a) incubating the cells with a monoclonal antibody, as described above, which is labeled, and (b) detecting the presence of bound antibody. Within another aspect, a method for detecting soluble IL-1 receptor in serum is provided comprising the steps of (a) incubating serum suspected of containing soluble IL-1 receptor with a solid support having monoclonal antibodies as described above affixed thereto under conditions and for a time sufficient for binding to occur, (b) incubating the solid support with a second labeled monoclonal antibody specific for mammalian IL-1 receptors under conditions and for a time sufficient for binding to occur, and (c) detecting the presence of bound labeled antibody.
These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.
REFERENCES:
patent: 4411993 (1983-10-01), Gillis
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4675285 (1987-06-01), Clark et al.
patent: 4707443 (1987-11-01), Nelson et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5006459 (1991-04-01), Kung et al.
patent: 5043281 (1991-08-01), Masuho et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 1053300 (1989-03-01), None
Muchmore et al. (1985) Science 229:479-481.*
Potocnjak et al. (1982) Science 215:1637-1639.*
Malavarca, R., et al., Program & Abstrcts for the Fifth International Lymphokine Workshop, Jan. 11-15, 1987, Clearwater, Florida, as published in Lymphokine Research, vol. 6, No. 1, Abstract No. 1238 (Winter, 1987).*
Paganelli, K.A., et al., The Journal of Immunology, vol. 138, No. 7, pp. 2249-2253, Apr., 1987.*
Harris et al. TibTech 11: 42-44 (1993).*
D'Narello et al. Blood 77:1627-1652 (1991).*
Steiner et al. BioTechnology 11:644 (1993).*
Rhem BioTechnology Newswatch Oct. 4, 1993 p. 1 (1993).*
Weir Handbook Exper. Immunology 4th ed. 1986 pp. 8.14-8.15.*
All other ref's of record.*
Craig Bioworld Today Jul. 19, 1994 p.1,3.*
Faherty et al. J. Immunol. 148:766-771 (1992).*
Sims et al. PNAS 86:8946-8950 (1989).*
Dower et al. J. Immunol 142:4314-4320 (1989).*
Scopes (1987) Protein Purification-Principles and Practice, 2d ed., Springer-Verlag, N.Y., pp. vii-viii and Table of Contents.*
Sims et al. PNAS 90:6155-6159 (1993) (Cited by Applicant not Provided).*
Lennard Crit. Rev. Immunol. 15(1) 77-105 (1995).*
Rangnekar et al., “Immunoprecipitation of interleukin-1 receptors from a mouse thymoma cell line, EL-4,”J. Biol. Chem.263:16408, 1988.
Rangnekar and Plate, Interleukin-1 receptor-like proteins synthesized by translation, in vitro, of immunopurified polysomal messenger RNA,J. Biol. Chem.263:16414, 1988.
Bomsztyk et al., “Evidence for different interleukin-1 receptors in murine B- and T-cell lines,”Proc. Natl. Acad. Sci. USA86:8034, 1989.
Chizzonite et al., “Two high-affinity interleukin 1 receptors represent separate gene products,”Proc. Natl. Acad. Sci. USA86:8029, 1989.
Dower, et al., “Retention of ligand binding activity by the extracellular domain of the IL-1 receptor,”J. Immunol.142:4314,1989.
Gallis et al., “IL-1 induces rapid phosphorylation of the IL-1 receptor,”J. Immunol.143:3235, 1989.
Slack et al., “Application of the multiscreen system to cytokine radioreceptor assays,”BioTechniques7:1132, 1989.
Curtis et al., “IL-1 and its receptor are translocated to the nucleus,”J. Immunol.144:1295, 1990.
Lewis et al., “Monoclonal antibodies reacting with the interleukin 1 receptor define a multi-molecular complex,”Eur. J. Immunol.20:207, 1990.
Dower et al., “Similarity between the interleukin 1 receptors on a murine T-lymphoma cell line and on a murine fibroblast cell line,”Proc. Natl. Acad. Sci. USA83:1060, 1986.
Kilian et al., “Interleukin 1a and interleukin 1b bind to the same receptor on T cells,”J. Immunol.136:4509, 1986.
Matsushima et al., “Properties of a specific interleukin 1 receptor on human Epstein Barr virus-transformed . . . ”J. Immunol.136:4496, 1986.
Bird et al., “Identifications of a common class of high affinity receptors for both types of porcine interleukin-1 on connective tissue cells,”Nature324:263, 1986.
Dower et al., The cell surface receptors for interleukin-1a and interleukin-1b are indentical,Nature324:266, 1986.
Bron and MacDonald, Identification of the plasma membrane receptor for interleukin-1 on mouse thymoma cells,FEBS Lett.219:365, 1987.
Chin et al, “Identification of a high-affinity receptor for native human interleukin 1b and interleukin 1a on normal human lung fibroblasts,”J. Exp. Med.165:
Dower Steven K.
March Carl J.
Sims John E.
Urdal David L.
Gambel Phillip
Henry Janis C.
Immunex Corporation
LandOfFree
Antibodies to interleukin-1 receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to interleukin-1 receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to interleukin-1 receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3044140